<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1204</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2005-1-3-60-65</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Experience of Cancer Research Center in the treatment of advanced germ cell tumors</article-title><trans-title-group xml:lang="ru"><trans-title>Опыт Российского онкологического научного центра в лечении пациентов с распространенными герминогенными опухолями</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tyulyandin</surname><given-names>S. A.</given-names></name><name xml:lang="ru"><surname>Тюляндин</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tryakin</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Трякин</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bulanov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Буланов</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Figurin</surname><given-names>K. M.</given-names></name><name xml:lang="ru"><surname>Фигурин</surname><given-names>К. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fainshtein</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Файнштейн</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Polotskiy</surname><given-names>B. E.</given-names></name><name xml:lang="ru"><surname>Полоцкий</surname><given-names>Б. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mitin</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Митин</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zaharova</surname><given-names>T. I.</given-names></name><name xml:lang="ru"><surname>Захарова</surname><given-names>Т. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Garin</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Гарин</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГУ РОНЦ им. Н.Н. Блохина РАМН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2005-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2005</year></pub-date><volume>1</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>60</fpage><lpage>65</lpage><history><date date-type="received" iso-8601-date="2020-02-19"><day>19</day><month>02</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-02-19"><day>19</day><month>02</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1204">https://oncourology.abvpress.ru/oncur/article/view/1204</self-uri><abstract xml:lang="en"><p>The experience of CRC in the treatment of advanced germ cell tumors is reported. The analysis of factors influencing prognosis and treatment tactics is carried out. Contemporary conception of advanced germ cell tumors treatment implies the initial use of platinum based chemotherapy. After completion of chemotherapy, surgical removal of residual tumor (retroperitoneal and mediastinal lymph nodes, lung and liver metastases) carries diagnostic and curative means. Such approach allows curing 50-90% of patients depending on prognostic factors. Results of induction chemotherapy for relapses of germ cell tumors are presented separately. Treatment of this condition comprises chemotherapy with inclusion of ifosfamid or taxanes with following cytoreductive surgery. This modality allows long term remission in the fourth of patients with relapse of germ cell tumors.</p></abstract><trans-abstract xml:lang="ru"><p>.</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Silverberg E. Statistical and epidemiological data on urological cancer //Cancer. — 1987. — V. 60. — Р. 692—717.</mixed-citation><mixed-citation xml:lang="ru">Silverberg E. Statistical and epidemiological data on urological cancer //Cancer. — 1987. — V. 60. — Р. 692—717.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Альмяшев А.З., Кулаев М.Т., Бегоулов И.В. и др. Клиника, диагностика и лечение злокачественных опухолей яичка. Методические указания для врачей и студентов. — Саранск, 2001. — 28 с.</mixed-citation><mixed-citation xml:lang="ru">Альмяшев А.З., Кулаев М.Т., Бегоулов И.В. и др. Клиника, диагностика и лечение злокачественных опухолей яичка. Методические указания для врачей и студентов. — Саранск, 2001. — 28 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Тюляндин С.А., Насырова Р.Ю., Стенина М.Б. и др. Гранулоцитарно-макрофагальный колониестимулирующий фактор при совместном применении с комбинированной химиотерапией карбоплатином и фосфамидом у больных диссеминированной семиномой // Вестн. ОНЦ. — 1992;2: 36—45.</mixed-citation><mixed-citation xml:lang="ru">Тюляндин С.А., Насырова Р.Ю., Стенина М.Б. и др. Гранулоцитарно-макрофагальный колониестимулирующий фактор при совместном применении с комбинированной химиотерапией карбоплатином и фосфамидом у больных диссеминированной семиномой // Вестн. ОНЦ. — 1992;2: 36—45.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Horwich A., Sleiifer D.T., Fossa S.D. et al. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic non-seminomatous germ cell cancer: A multi-institutional Medical Research Council/ European Organization for Research and Treatment of Cancer trial // J. Clin. Oncol. — 1997; 15: 1844—1852.</mixed-citation><mixed-citation xml:lang="ru">Horwich A., Sleiifer D.T., Fossa S.D. et al. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic non-seminomatous germ cell cancer: A multi-institutional Medical Research Council/ European Organization for Research and Treatment of Cancer trial // J. Clin. Oncol. — 1997; 15: 1844—1852.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Tjulandin S., Garin A., Stenina M. et al. Carboplatin (CBDCA), etoposide (VP-16), bleomycin (B) and GM-CSF in patients with poor-risk nonseminomatous germ cell tumors (NSGCT). — Proc. ASCO. 1993. — Аb. 776.</mixed-citation><mixed-citation xml:lang="ru">Tjulandin S., Garin A., Stenina M. et al. Carboplatin (CBDCA), etoposide (VP-16), bleomycin (B) and GM-CSF in patients with poor-risk nonseminomatous germ cell tumors (NSGCT). — Proc. ASCO. 1993. — Аb. 776.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: A prognostic Factor-Based Staging System for Metastatic Germ Cell Cancers // J. Clin. Oncol. — 1997; 15: 594—603.</mixed-citation><mixed-citation xml:lang="ru">International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: A prognostic Factor-Based Staging System for Metastatic Germ Cell Cancers // J. Clin. Oncol. — 1997; 15: 594—603.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Трякин А.А. Современные факторы прогноза при диссеминированных герминогенных опухолях у мужчин.: Дис... канд. мед. наук. — М., 2003. — 137 с.</mixed-citation><mixed-citation xml:lang="ru">Трякин А.А. Современные факторы прогноза при диссеминированных герминогенных опухолях у мужчин.: Дис... канд. мед. наук. — М., 2003. — 137 с.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Fossa S.D., Oliver R.T.D., Stenning S.P. et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy // Eur. J. Canc. — 1997; 96: 1—8.</mixed-citation><mixed-citation xml:lang="ru">Fossa S.D., Oliver R.T.D., Stenning S.P. et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy // Eur. J. Canc. — 1997; 96: 1—8.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. George D.W., Foster R.S., Hromas R.A. et al. Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis // J. Clin. Oncol. — 2003; 21, 1: 113—122.</mixed-citation><mixed-citation xml:lang="ru">George D.W., Foster R.S., Hromas R.A. et al. Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis // J. Clin. Oncol. — 2003; 21, 1: 113—122.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Loehrer P.J., Lauer R., Roth B.J. et al. Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide // Ann. Intern. Med. — 1988; 109: 540—546.</mixed-citation><mixed-citation xml:lang="ru">Loehrer P.J., Lauer R., Roth B.J. et al. Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide // Ann. Intern. Med. — 1988; 109: 540—546.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Rick O., Bokemeyer C., Beyer J. et al. Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer // J. Clin. Oncol. — 2001; 1:81—88.</mixed-citation><mixed-citation xml:lang="ru">Rick O., Bokemeyer C., Beyer J. et al. Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer // J. Clin. Oncol. — 2001; 1:81—88.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Тюляндин С.А. Лечение диссеминированных герминогенных опухолей у мужчин: Дис... докт. мед. наук. — М., 1993. — 182 с.</mixed-citation><mixed-citation xml:lang="ru">Тюляндин С.А. Лечение диссеминированных герминогенных опухолей у мужчин: Дис... докт. мед. наук. — М., 1993. — 182 с.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
